Belinda Gonzalez
Family Medicine · Corpus Christi, TXNPI 1730389610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 889 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,983 and has fallen 90.2% since, to $292 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 889 payments — averaging $13.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$868
- Amgen$826
- Amarin Pharma, Inc.$792
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$601%
- Food & beverage$11,58699%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 263 | $2,458 |
| AstraZeneca | 87 | $1,631 |
| Lilly USA, LLC | 63 | $1,037 |
| Boehringer Ingelheim | 59 | $868 |
| Amgen(2 entities) | 64 | $826 |
| Amarin Pharma, Inc. | 54 | $792 |
| Astellas Pharma US Inc | 33 | $560 |
| GSK | 33 | $459 |
| Sanofi-aventis U.S. LLC | 26 | $383 |
| Merck | 33 | $379 |
| Pfizer | 29 | $376 |
| AbbVie(2 entities) | 26 | $294 |
| Johnson & Johnson | 13 | $193 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $170 |
| Biohaven Pharmaceuticals, Inc. | 18 | $169 |
| Teva Pharmaceuticals USA, Inc. | 17 | $168 |
| Bayer | 2 | $147 |
| Aytu Biopharma, Inc. | 10 | $138 |
| Kowa Pharmaceuticals America, Inc. | 6 | $102 |
| Novartis | 4 | $75 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Sanofi | 1 | $60 |
| Exact Sciences | 2 | $54 |
| Dexcom, Inc. | 3 | $52 |
| Shire North American Group Inc | 3 | $44 |
| Inspire Medical Systems, Inc. | 1 | $43 |
| Neos Therapeutics, LP | 2 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$125
- FARXIGA$102
- BREZTRI AEROSPHERE$102
- SYMBICORT$102
How this compares
$11,761 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 20 | $228 |
| Amlodipine Besylate | 18 | $111 |
| Lisinopril | 12 | $82 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Corpus Christi
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.